Diversified Trust Co lowered its stake in shares of Ascendis Pharma A/S (NASDAQ:ASND – Free Report) by 12.0% during the 1st quarter, HoldingsChannel.com reports. The fund owned 37,161 shares of the biotechnology company’s stock after selling 5,090 shares during the quarter. Diversified Trust Co’s holdings in Ascendis Pharma A/S were worth $8,500,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also recently modified their holdings of ASND. Advisory Services Network LLC acquired a new stake in shares of Ascendis Pharma A/S during the third quarter worth $26,000. Arax Advisory Partners increased its position in shares of Ascendis Pharma A/S by 212.2% in the 4th quarter. Arax Advisory Partners now owns 153 shares of the biotechnology company’s stock valued at $33,000 after acquiring an additional 104 shares during the period. Leonteq Securities AG purchased a new position in Ascendis Pharma A/S in the 4th quarter worth $36,000. Caitong International Asset Management Co. Ltd purchased a new position in Ascendis Pharma A/S in the 4th quarter worth $42,000. Finally, Jones Financial Companies Lllp raised its stake in Ascendis Pharma A/S by 57.2% in the 3rd quarter. Jones Financial Companies Lllp now owns 228 shares of the biotechnology company’s stock worth $44,000 after acquiring an additional 83 shares during the last quarter.
Ascendis Pharma A/S Stock Performance
Shares of Ascendis Pharma A/S stock opened at $230.83 on Friday. The firm has a 50-day simple moving average of $232.32 and a two-hundred day simple moving average of $224.27. The company has a debt-to-equity ratio of 0.79, a quick ratio of 0.72 and a current ratio of 1.00. Ascendis Pharma A/S has a fifty-two week low of $160.86 and a fifty-two week high of $250.74. The company has a market cap of $14.40 billion, a P/E ratio of 26.62 and a beta of 0.39.
Insider Buying and Selling at Ascendis Pharma A/S
In other news, Director Jean Jacques Bienaime acquired 400 shares of Ascendis Pharma A/S stock in a transaction that occurred on Tuesday, May 26th. The stock was purchased at an average cost of $237.80 per share, with a total value of $95,120.00. Following the purchase, the director owned 400 shares in the company, valued at $95,120. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Flemming Steen Jensen sold 19,460 shares of the stock in a transaction dated Monday, May 11th. The shares were sold at an average price of $238.49, for a total transaction of $4,641,015.40. The SEC filing for this sale provides additional information. 40.00% of the stock is currently owned by insiders.
Wall Street Analysts Forecast Growth
ASND has been the topic of several research analyst reports. Cantor Fitzgerald reiterated an “overweight” rating and set a $300.00 price target on shares of Ascendis Pharma A/S in a research note on Monday, March 2nd. Wolfe Research reaffirmed an “outperform” rating and set a $260.00 target price on shares of Ascendis Pharma A/S in a report on Monday, March 2nd. Royal Bank Of Canada upped their target price on Ascendis Pharma A/S from $250.00 to $275.00 and gave the company an “outperform” rating in a research report on Monday, March 2nd. Evercore reiterated an “outperform” rating and issued a $329.00 target price on shares of Ascendis Pharma A/S in a research report on Friday, May 15th. Finally, Barclays increased their price target on shares of Ascendis Pharma A/S from $342.00 to $345.00 and gave the stock an “overweight” rating in a report on Monday, May 11th. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, Ascendis Pharma A/S has an average rating of “Buy” and a consensus price target of $295.39.
Get Our Latest Analysis on ASND
Ascendis Pharma A/S Company Profile
Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.
The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.
Featured Stories
- Five stocks we like better than Ascendis Pharma A/S
- 3 Retail Winners Using Cash Flow to Stay Ahead
- 3 Tech ETFs That Could Bounce Back After the AI Selloff
- 3 Penny Stocks Under $5 Backed by Real Revenue Growth
- 3 Non-Pharma Firms That Could Benefit From the GLP-1 Trend
Want to see what other hedge funds are holding ASND? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ascendis Pharma A/S (NASDAQ:ASND – Free Report).
Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.
